

PERCUS.113A

CUSTOMER NO.: 20995

TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321

9

Applicant : Gholam-Reza Zadno-Azizi
Appl. No. : 10/035,389
Filed : December 28, 2001
For : METHODS AND APPARATUSES
FOR DRUG DELIVERY TO AN
INTRAVASCULAR OCCLUSION
Examiner : Mark K. Han
Group Art Unit : 3763

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

January 6, 2004

(Date)

David L. Hauser, Reg. No. 42,643

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Empowerment of Attorney

Pursuant to 37 C.F.R. § 1.321(b) the undersigned attorney of record is empowered to act on behalf of the Assignee, Medtronic AVE, Inc. ("Assignee").

Right of Assignee and Ownership

In accordance with 37 C.F.R. § 3.73(b), Assignee represents that it is the owner of the entire right, title and interest in the above-identified application and co-owned Application No. 09/049,857, now U.S. Patent No. 6,135,991, by virtue of assignments recorded at Reel No. 012437, Frame No. 0255 and Reel No. 9274, Frame No. 0333 by the Assignment Branch of the Patent and Trademark Office. The Assignee represents that, to the best of Assignee's knowledge and belief, title is in the Assignee seeking to take action.

01/14/2004 BABRAHA1 00000030 10035389

01 FC:1814

110.00 OP

Disclaimer by Assignee

Assignee hereby disclaims, except as provided below, the terminal part of any patent granted on the above-identified application that would extend beyond the expiration date of the full

Appl. No. : 10/035,389
Filed : December 28, 2001

statutory term of U.S. Patent No. 6,135,991, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the above-identified application and U.S. Patent No. 6,135,991 are co-owned. This agreement extends to any patent granted on the above-identified application and shall be binding on its successors or assigns.


Assignee does not disclaim any terminal part of any patent granted on the above-identified application that would extend to the expiration date of the full statutory term of U.S. Patent No. 6,135,991 in the event that U.S. Patent No. 6,135,991 later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title stated above.

This Terminal Disclaimer is accompanied by the \$110 fee set forth in 37 C.F.R. § 1.20(d).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 6, 2004

By: 
David L. Hauser
Registration No. 42,643
Attorney of Record
Customer No. 20,995
(949) 721-7624

\\DOCS-OC\FILES\DOCS\DLH\PERCUSURGE\113\113A_TD.DOC
010604